168 related articles for article (PubMed ID: 19729435)
1. ESRD as a window into America's cost crisis in health care.
Knauf F; Aronson PS
J Am Soc Nephrol; 2009 Oct; 20(10):2093-7. PubMed ID: 19729435
[No Abstract] [Full Text] [Related]
2. [Cost-effectiveness analysis of treatment for end-stage renal disease].
Asgeirsdóttir TL; Asmundsdóttir G; Heimisdóttir M; Jónsson E; Pálsson R
Laeknabladid; 2009 Nov; 95(11):747-53. PubMed ID: 19996463
[TBL] [Abstract][Full Text] [Related]
3. Drugs take the spotlight in steering clinical, economic direction for ESRD.
Neumann ME
Nephrol News Issues; 2004 Jun; 18(7):50-1. PubMed ID: 15232997
[No Abstract] [Full Text] [Related]
4. Valuing prevention: discounting health benefits and costs in New Zealand.
Milne R
N Z Med J; 2005 May; 118(1214):U1443. PubMed ID: 15886738
[No Abstract] [Full Text] [Related]
5. [Readers' letters concerning F. Keller et al: "Financial incentives and dialysis"].
Dehnert HG
Med Klin (Munich); 2008 Jan; 103(1):47-8; author reply 51. PubMed ID: 18338429
[No Abstract] [Full Text] [Related]
6. The cost of hemodialysis in Iran.
Arefzadeh A; Lessanpezeshki M; Seifi S
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):307-11. PubMed ID: 19237828
[TBL] [Abstract][Full Text] [Related]
7. [Financial barriers and peritoneal dialysis].
Chanliau J
Nephrol Ther; 2009 Jun; 5 Suppl 4():S290-2. PubMed ID: 19596351
[TBL] [Abstract][Full Text] [Related]
8. [The obligation to evaluate health care].
Martín Escobar E
Nefrologia; 2001; 21(4):340-1. PubMed ID: 11816508
[No Abstract] [Full Text] [Related]
9. Ready or not.
Maklebust J; Margolis D
Adv Wound Care; 1996; 9(4):6. PubMed ID: 9069738
[No Abstract] [Full Text] [Related]
10. Consumption costs and earnings during added years of life - a reply to Nyman.
Gandjour A
Health Econ; 2006 Mar; 15(3):315-7; discussion 319-22. PubMed ID: 16444762
[No Abstract] [Full Text] [Related]
11. Telemedicine project looks to improve ESRD care, lower costs. TRC/Georgetown University Medical Center begin two-year experiment.
Neumann ME
Nephrol News Issues; 1997 Oct; 11(10):67-9. PubMed ID: 9391397
[No Abstract] [Full Text] [Related]
12. On survival consumption costs: a reply to Nyman.
Lundin D; Ramsberg J
Health Econ; 2008 Feb; 17(2):293-7. PubMed ID: 17891823
[No Abstract] [Full Text] [Related]
13. Value of health care expenditures.
Aspaas PK
S D Med; 2006 Dec; 59(12):506. PubMed ID: 17212179
[No Abstract] [Full Text] [Related]
14. Money matters: what to look for in an economic analysis.
Dijksman LM; Poolman RW; Bhandari M; Goeree R; Tarride JE;
Acta Orthop; 2008 Feb; 79(1):1-11. PubMed ID: 18283565
[No Abstract] [Full Text] [Related]
15. Costs and consequences of ESRD in NC.
Norman M; Young H; Bell RA
N C Med J; 1997; 58(3):165. PubMed ID: 9164124
[No Abstract] [Full Text] [Related]
16. [Health economy assessments--how to find them].
Alton V; Eckerlund I; Norlund A
Lakartidningen; 2006 May 31-Jun 6; 103(21-22):1726-33. PubMed ID: 16826717
[No Abstract] [Full Text] [Related]
17. Budget impact analysis and its rational basis.
Hilden J
Med Decis Making; 2008; 28(4):460-1. PubMed ID: 18660488
[No Abstract] [Full Text] [Related]
18. On the lottery equivalents method: a response to Spencer et al.
Oliver A
Health Econ; 2006 Mar; 15(3):323-5. PubMed ID: 16432804
[No Abstract] [Full Text] [Related]
19. Prolonged mechanical ventilation is even more expensive.
Udeh CI
Crit Care Med; 2007 Dec; 35(12):2881; author reply 2881-2. PubMed ID: 18043220
[No Abstract] [Full Text] [Related]
20. A patient-directed fee-for-service system can work for ESRD.
Amerling R
Nephrol News Issues; 2002 Sep; 16(10):25-6. PubMed ID: 12271926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
